Drug
Apixaban Placebo
Apixaban Placebo is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
active_not_recruiting125%
completed375%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
completedphase_2
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03251482
completedphase_3
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683
completedphase_2
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
NCT00097357
Clinical Trials (4)
Showing 4 of 4 trials
NCT05757869Phase 3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT03251482Phase 2
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
NCT00371683Phase 3
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00097357Phase 2
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4